Avaliação do polimorfismo de fármacos utilizados para produção de medicamentos genéricos no Brasil

O polimorfismo é definido como a tendência de uma substância em se cristalizar em diferentes estados cristalinos. A presença de diversas formas cristalinas diferentes para um mesmo fármaco pode alterar algumas das propriedades físico-químicas da substância, dentre as quais a sua solubilidade, o que pode afetar diretamente o seu perfil de dissolução. O objetivo do trabalho foi revisar a literatura sobre os métodos de detecção de polimorfismo dos fármacos e avaliar diferentes amostras de carbamazepina disponíveis no Brasil visando identificar a presença de diferente polimorfos. A carbamazepina apresentou indícios de polimorfismo no DSC para algumas das cinco amostras, o que não foi confirmado pelos demais métodos empregados (IV e raio-X). Após os testes de dissolução, os perfis foram comparados com a amostra de referência e apenas uma das amostras apresentou perfil de dissolução semelhante quando comparado ao padrão através do cálculo de f1 e f2. Os resultados observados na etapa prática sinalizam que se faz necessário o desenvolvimento e aprofundamento do assunto junto à Anvisa com vistas à preservação da segurança dos medicamentos dos medicamentos genéricos comercializados no País.

Micropartículas de p(hbhv) e de blendas de p(hbhv):pcl contendo dexametasona ou acetato de dexametasona como modelos de fármacos : caracterização físico-química e perfis de liberação in vitro

Tendo em vista o controle da porosidade da matriz polimérica de micropartículas constituídas por blendas de poli(hidroxibutirato-co-hidroxivalerato) [P(HBHV)] e de poli- ε-caprolactona (PCL), o presente trabalho objetivou verificar a possibilidade de controle da liberação de fármacos associados a esses sistemas. Foram preparadas micropartículas constituídas de blendas de P(HBHV):PCL nas proporções de 100:0, 90:10 e 80:20 (m/m) pelo método de emulsificação/evaporação de solvente, variandose o volume de fase orgânica. Os modelos de fármacos utilizados foram a dexametasona e o acetato de dexametasona. As micropartículas obtidas apresentaram rendimento e eficiência de encapsulação satisfatória, entretanto, através de análises por microscopia óptica e microscopia eletrônica de varredura foi evidenciada a ocorrência de cristais de fármaco não encapsulado. Os diâmetros de partícula permaneceram em torno de 100 a 200 μm e variaram em função do volume de fase orgânica. A área superficial foi afetada pelo percentual de PCL na blenda e pela presença de cristais do fármaco nas formulações. A análise térmica das amostras demonstrou que o processo de obtenção alterou a estrutura cristalina do P(HBHV) e que a encapsulação dos fármacos levou à variação da sua temperatura de transição vítrea e cristalinidade. Os perfis de dissolução da dexametasona a partir das micropartículas apresentaram ajustes adequados ao modelo monoexponencial e foram semelhantes aos perfis apresentados pelo fármaco não encapsulado. Nas formulações contendo acetato de dexametasona houve liberação sustentada do fármaco por até 250 horas quando associado aos sistemas e a modelagem matemática indicou ajuste dos perfis ao modelo biexponencial. Evidenciou-se um aumento nos valores das constantes de liberação dos fármacos conforme o acréscimo do conteúdo de PCL na blenda.

Síntese e caracterização do poli(ácido láctico) para potencial uso em sistemas de liberação controlada de fármacos

With the advances in medicine, life expectancy of the world population has grown considerably in recent decades. Studies have been performed in order to maintain the quality of life through the development of new drugs and new surgical procedures. Biomaterials is an example of the researches to improve quality of life, and its use goes from the reconstruction of tissues and organs affected by diseases or other types of failure, to use in drug delivery system able to prolong the drug in the body and increase its bioavailability. Biopolymers are a class of biomaterials widely targeted by researchers since they have ideal properties for biomedical applications, such as high biocompatibility and biodegradability. Poly (lactic acid) (PLA) is a biopolymer used as a biomaterial and its monomer, lactic acid, is eliminated by the Krebs Cycle (citric acid cycle). It is possible to synthesize PLA through various synthesis routes, however, the direct polycondensation is cheaper due the use of few steps of polymerization. In this work we used experimental design (DOE) to produce PLAs with different molecular weight from the direct polycondensation of lactic acid, with characteristics suitable for use in drug delivery system (DDS). Through the experimental design it was noted that the time of esterification, in the direct polycondensation, is the most important stage to obtain a higher molecular weight. The Fourier Transform Infrared (FTIR) spectrograms obtained were equivalent to the PLAs available in the literature. Results of Differential Scanning Calorimetry (DSC) showed that all PLAs produced are semicrystalline with glass transition temperatures (Tgs) ranging between 36 - 48 °C, and melting temperatures (Tm) ranging from 117 to 130 °C. The PLAs molecular weight characterized from Size Exclusion Chromatography (SEC), varied from 1000 to 11,000 g/mol. PLAs obtained showed a fibrous morphology characterized by Scanning Electron Microscopy (SEM)

Novos sistemas de liberação de fármacos à base de xilana

The aim of this work was to perform the extraction and characterization of xylan from corn cobs and prepare xylan-based microcapsules. For that purpose, an alkaline extraction of xylan was carried out followed by the polymer characterization regarding its technological properties, such as angle of repose, Hausner factor, density, compressibility and compactability. Also, a low-cost and rapid analytical procedure to identify xylan by means of infrared spectroscopy was studied. Xylan was characterized as a yellowish fine powder with low density and poor flow properties. After the extraction and characterization of the polymer, xylan-based microcapsules were prepared by means of interfacial crosslinking polymerization and their characterization was performed in order to obtain gastroresistant multiparticulate systems. This work involved the most suitable parameters of the preparation of microcapsules as well as the study of the process, scale-up methodology and biological analysis. Magnetic nanoparticles were used as a model system to be encapsulated by the xylan microcapsules. According to the results, xylan-based microcapsules were shown to be resistant to several conditions found along the gastrointestinal tract and they were able to avoid the early degradation of the magnetic nanoparticles

Sistemas microemulsionados como carreador lipídico para fármacos insolúveis

Several pharmaceutical products have been developed in recent years aiming to enhance the treatment of diseases by increasing the effectiveness of drugs. Many of these new products are based on new drug delivery systems. Among these, microemulsions, which were first studied in 1943 by Hoar and Schulman, is of great interest. Microemulsion can be defined as a thermodynamically stable, isotropic, translucent and transparent system of two immiscible liquids stabilized by a surfactant film located in the oil / water interface. The aim os this work was the incorporation of Amphotericin B and Simvasatin to a microemulsion system and analyzes its physicochemical properties and their therapeutical activity when incorporated into this system. Some very promising results were achieved as the reduction of the toxicity and maintenance of the efficacy of the Amphotericin B incorpored into a microemulsion, which was demonstrated in the in vitro pharmacotoxicological study. As for the incorporation of Simvastatin in microemulsion, it was observed a significant improvement in the potential antiinflammatory and anti-infective properties when the system was use to treat infected wounds (simvastatin pleiotropic effects). Therefore, it can be concluded that the incorporation of these drugs into microemulsion system reveal the potential of microemulsions as a promising and novel dosage form, qualifying them for future trials in order to make them available in the pharmaceutical market

Desenvolvimento de sistemas magnéticos com potencialidades terapêuticas para vetorização de fármacos

Magnetic targeting is being investigated as a means of local delivery of drugs, combining precision, minimal surgical intervention, and satisfactory concentration of the drug in the target region. In view of these advantages, it is a promising strategy for improving the pharmacological response. Magnetic particles are attracted by a magnetic field gradient, and drugs bound to them can be driven to their site of action by means of the selective application of magnetic field on the desired area. Helicobacter pylori is the commonest chronic bacterial infection. The treatment of choice has commonly been based upon a triple therapy combining two antibiotics and an anti-secretory agent. Furthermore, an extended-release profile is of utmost importance for these formulations. The aim of this work was to develop a magnetic system containing the antibiotic amoxicillin for oral magnetic drug targeting. First, magnetic particles were produced by coprecipitation of iron salts in alkaline medium. The second step was coating the particles and amoxicillin with Eudragit® S-100 by spray-drying technique. The system obtained demonstrated through the characterization studies carried out a possible oral drug delivery system, consisting in magnetite microparticles and amoxicillin, coated with a polymer acid resistant. This system can be used to deliver drugs to the stomach for treatment of infections in this organ. Another important finding in this work is that it opens new prospects to coat magnetic microparticles by the technique of spray-drying.

Desenvolvimento de microemulsões liofilizadas como um potencial sistema de liberação de fármacos usando planejamento experimental fatorial

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Influência de fármacos lipofílicos na estabilidade de emulsões de uso terapêutico

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Avaliação citológica em base líquida de fármacos moduladores estrogênicos

Hormone therapy is an important tool in the treatment of breast cancer and tamoxifen represents one of the most important drugs used in this type of treatment. Recently other drugs based on the inhibition of aromatase had been developed, this enzyme is responsible for the synthesis of estrogenic esteroids from the androgenic ones. The objective of this study would be the development of a quantitative cytological model of murine estral analysis that allowed the characterization of different hormone drugs effect over vaginal epithelium. The technique of monochromatic staining with Evans blue (C.I. 23860) showed to be efficient in the qualitative and quantitative classification of the cycle. It had been observed differences in the cytological standard of animals submitted to the studied drugs; tamoxifen presented a widening of phases of lesser maturation (diestrais), while anastrozole and exemestane increased the duration of the phases of larger maturation (estrais). The data were analysed through a cubical non linear regression (spline) which allowed a better characterization of the drugs, suggesting a proper cytological profile to the antagonism of the estrogen receptor (tamoxifen), aromatase competition (anastrozole) and inhibition of the enzyme (exemestane)

Microemulsões e fases líquidas cristalinas como sistemas de liberação de fármacos

A mistura de tensoativos com água, em determinadas proporções, na ausência ou na presença de substâncias lipofílicas pode formar diferentes tipos de agregados, entre os quais agregados polimorfos representados pelas microemulsões (ME) e mesofases liotrópicas - os cristais líquidos (LC), que estão intimamente ligados com a proporção e a natureza dos componentes da mistura. Nesse trabalho, foi discutido o papel desses sistemas na incorporação de fármacos com diferentes propriedades físico-químicas, influenciando fortemente a liberação, assim como a biodisponibilidade dos fármacos. Aspectos sobre a formação e a caracterização de microemulsões e cristais líquidos também foram discutidos. A análise da literatura indicou que, dependendo da polaridade do fármaco, o efeito da ME ou LC pode ser usado para otimizar o efeito terapêutico por meio do controle da velocidade ou do mecanismo de liberação do fármaco.

Latenciação e formas avançadas de transporte de fármacos

O processo de modificação molecular denominado latenciação é revisto, apresentando formas avançadas no transporte de fármacos, utilizando macromoléculas como transportadores e sistemas de liberação sítio-específica como: CDS (Chemical Delivery System), ADEPT (Antibody-Directed Enzyme Prodrug Therapy), GDEPT/VDEPT (Gene-Directed Enzyme Prodrug Therapy/Vírus-Directed Enzyme Prodrug Therapy), ODDS (Osteotropic Drug Delivery System), PDEPT (Polymer-Directed Enzyme Prodrug Therapy), PELT (Polymer-Enzyme Liposome Therapy) e LEAPT (Lectin-Directed Enzyme-Activated Prodrug Therapy).

O processo de latenciação no planejamento de fármacos

Short review about the main aspects of prodrug design, as its objectives, applicability and importance, showing the new trends in the research for selective latent forms, namely targeted drugs.

Anemia falciforme: desafios e avanços na busca de novos fármacos

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)